BillionToOne DNA Tests: From Prenatal to Cancer Screening

BillionToOne began in 2017 when two PhD students, Ozan and David, launched a molecular diagnostics venture with just $300,000 and half a lab bench. Their core mission is to make genetic testing universally accessible and affordable, focusing on detecting DNA shed by tissues into the bloodstream.

The “Needle in a Haystack” Problem

Detecting fetal conditions or cancer from maternal blood means finding a single base‑pair difference among billions of DNA fragments. Traditional methods amplify all DNA, creating “tremendous noise” that drowns out the signal. The company’s name, “Billion to One,” captures the scale of this detection challenge: one distinct base pair out of three billion.

Technical Innovation: Synthetic DNA and Error Correction

BillionToOne solves the noise problem by adding proprietary synthetic DNA—Quantitative Counting Templates—to each patient sample before amplification. Because the synthetic molecules are known, the company can measure how PCR bias distorts them and then subtract that noise using AI and computer‑vision tools. As one founder put it, “That converts a difficult biology problem to almost a simple mathematical problem.” This approach enables ultra‑sensitive detection of both fetal genetic abnormalities and cancer markers.

Noise‑Reduction Workflow

1. Spike known synthetic DNA into the sample.
2. Perform PCR amplification on the combined mixture.
3. Sequence the product and compare the synthetic DNA’s observed versus expected readout.
4. Apply machine‑learning models to remove the measured bias, revealing the true biological signal.

Scaling and Commercialization

The company now processes more than 600,000 tests per year, capturing close to 20 % of the market. Initial growth came from direct‑to‑consumer marketing of prenatal tests, which generated patient demand and persuaded physicians to adopt the technology. BillionToOne went public in late 2023 with a valuation exceeding $4 billion, and it aims to expand capacity to two million tests annually using its existing facilities.

Future Roadmap: The “Holy Grail” of Cancer Detection

BillionToOne follows a three‑step plan: first, prenatal genetics; second, a liquid‑biopsy product for late‑stage cancer (Northstar Select); and third, early‑stage cancer detection. The current focus is an ultra‑sensitive Minimal Residual Disease (MRD) test for stage‑one cancer patients. The ultimate vision is annual, population‑wide screening that catches cancer before it reaches stage one.

Organizational Philosophy

The firm hires “interdisciplinary people” rather than merely forming interdisciplinary teams, allowing each employee to bring a broad skill set to the table. R&D operates as many small “startups” within the company, with principal investigators owning products end‑to‑end. The founders emphasize that “pressure is a privilege,” fostering a high‑growth, high‑challenge environment.